Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis

Hepatitis B Clinical Trial

Official title: Re-compensation and Its Clinical Characteristics in Treatment-naïve HBV Decompensated Cirrhosis on Antiviral Therapy

Status Not yet recruiting

Clinical Trial Summary

In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage). Patients were followed up every 6 months until death /liver transplantation or for 5 years. Clinical data from medical records about past history, first decompensated events, second /further decompensated events, HCC, and death/ liver transplantation were retrospectively collected. In this retrospective study, the incidence of re-compensation and its clinical characteristics were mainly explored.

Clinical Trial Description

In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage). Patients were followed up every 6 months until death /liver transplantation or for 5 years. WBC, RBC, HGB, PLT, CRP, PT, PTA, INR, ALT, AST, TB, DB, ALB, GLO, ALP, GGT, CHE, BUN, Cr, Na, GLU, CHOL, TG, HDL-C, LDL-C, AFP, HBsAg, HBV-DNA, LSM, BUS, MRI/CT and gastroscope from medical records about past history, first decompensated events, second /further decompensated events, HCC, and death/ liver transplantation were retrospectively collected. This retrospective study aimed to explore the incidence of re-compensation and its clinical characteristics. ;

Related Conditions & MeSH terms

• Decompensated Cirrhosis
• Fibrosis
• Hepatitis B
• Liver Cirrhosis

• NCT number: NCT05086536
• Study type: Observational
• Source: Beijing Friendship Hospital
• Contact: Hong You, Doctor
• Phone: 861063139019
• Email: youhong30@sina.com
• Status: Not yet recruiting
• Start date: October 15, 2021
• Completion date: December 30, 2022